HB Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

HB Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$289K	Buy	+5,296	New	+$279K	﹤0.01%	1396
2024 Q2	–	Sell	-4,101	Closed	-$280K	–	939
2024 Q1	$280K	Buy	4,101 +791	+24%	+$56.6K	﹤0.01%	684
2023 Q4	$207K	Buy	+3,310	New	+$183K	﹤0.01%	733
2022 Q4	–	Sell	-4,452	Closed	-$291K	–	695
2022 Q3	$291K	Sell	4,452 -100	-2%	-$7.25K	0.01%	444
2022 Q2	$277K	Buy	4,552 +750	+20%	+$44.1K	0.01%	458
2022 Q1	$239K	Hold	3,802	–	–	﹤0.01%	512
2021 Q4	$288K	Buy	+3,802	New	+$332K	0.01%	398

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

HB Wealth Management's CRSP Position: Q2 2026 in Review

HB Wealth Management opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 5,296 shares worth $289K. The stake represents ﹤0.01% of the portfolio and ranks #1396 among its holdings. This is a return to the name: HB Wealth Management previously reported a position in CRSP as recently as Q1 2024.

HB Wealth Management first reported a position in CRSP in Q4 2021 and has held it in 7 quarters since. The position peaked at $291K in Q3 2022. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

HB Wealth Management held 5,296 shares of CRISPR Therapeutics worth $289K as of Q2 2026.
CRISPR Therapeutics was a new HB Wealth Management position in Q2 2026.
CRISPR Therapeutics made up ﹤0.01% of HB Wealth Management's portfolio in Q2 2026, its #1396 holding.
HB Wealth Management first reported a position in CRISPR Therapeutics in Q4 2021 and has held it in 7 quarters since.
HB Wealth Management's CRISPR Therapeutics position peaked at $291K in Q3 2022.
524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on HB Wealth Management's 13F filing for Q2 2026, filed 29 Jul 2026.